School of Dentistry, National Taiwan University, Taipei, Taiwan.
National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.
Oral Dis. 2022 Sep;28(6):1484-1495. doi: 10.1111/odi.13827. Epub 2021 Mar 13.
The myeloid-derived suppressor cells (MDSCs) frequently have a high expansion in cancer patients. This research explored whether administration of β-glucan could increase anti-tumor immunity in oral squamous cell carcinoma (OSCC) patients.
This study evaluated the MDSC level of circulating blood as CD33 /CD11b /HLA-DR by flow cytometry in 30 healthy donors (HDs, group I), in 48 oral squamous cell carcinoma (OSCC) patients before and after 14-day preoperative administration of β-glucan (group II), and in 52 OSCC patients without taking β-glucan (group III).
A significantly higher mean MDSC level was observed in 100 OSCC patients than in 30 HDs (p < .001). There was a significant reduction of the mean MDSC level in group II patients after taking β-glucan (p < .001). Moreover, we discovered a significantly higher recurrence-free survival (RFS) in group II than in group III patients (p = .026). Finally, the multivariate Cox regression further identified the MDSC level ≤1% and administration of β-glucan as more favorable prognostic factors for OSCC patients.
Preoperative administration of β-glucan can augment anti-tumor immunity and increase RFS rate via subversion of suppressive function of MDSC in OSCC patients.
髓系来源的抑制细胞（MDSCs）在癌症患者中经常大量扩增。本研究旨在探讨β-葡聚糖给药是否能增强口腔鳞状细胞癌（OSCC）患者的抗肿瘤免疫。
本研究通过流式细胞术评估了 30 名健康供者（I 组）、48 名 OSCC 患者术前 14 天给予β-葡聚糖（II 组）前后以及 52 名未服用β-葡聚糖的 OSCC 患者（III 组）循环血液中 CD33/CD11b/HLA-DR 的 MDSC 水平。
100 例 OSCC 患者的平均 MDSC 水平明显高于 30 例健康供者（p<0.001）。服用β-葡聚糖后，II 组患者的平均 MDSC 水平显著降低（p<0.001）。此外，我们发现 II 组患者的无复发生存率（RFS）明显高于 III 组患者（p=0.026）。最后，多变量 Cox 回归进一步确定 MDSC 水平≤1%和β-葡聚糖给药为 OSCC 患者更有利的预后因素。
术前给予β-葡聚糖可通过抑制 MDSC 的抑制功能增强 OSCC 患者的抗肿瘤免疫，并提高 RFS 率。
